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Abstract: A tethered MsDPEN-ruthenium catalyst reduces a series of isoxazolium salts, affording 
optically-active Δ4-isoxazolines in moderate to good yields and enantioenrichment. The redundancy 
for heating or high pressures allowed for chemoselective reduction with no subsequent heterocyclic 
ring opening. Results obtained reinforce our understanding of the workings of these Noyori-class 
catalysts. 
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Nitrogen containing heterocycles are one of the most prevalent structural motifs in biologically active 
compounds. Isoxazolines, in particular are valuable synthons en route to prized compounds such as 
alkaloids,1 steroids2 and amino acids3/sugars.4 Moreover, they exhibit a wide-spectrum of biological 
activities, rendering them among others, effective acaricidal,5 anti-cancer6 and anti-microbial agents.7 
A routine approach in the preparation of isoxazolines involves the [3+2]-dipolar cycloaddition 
between nitrones and alkenes/alkynes.8 Recently, the gold(I) catalyzed intramolecular cyclization of 
propargylic N-hydroxylamines has been reported.9 Retrosynthetic analysis reveal a possible approach 
for the synthesis of enantioenriched Δ4-isoxazolines will be the chemo- and stereoselective reduction 
of the C=N bond in isoxazoles. However, inherent challenges especially for the reduction of 
heteroarenes bearing adjacent heteroatoms include: a) difficulty in the dearomatization of isoxazoles, 
comparably more arduous than oxazoles and furans,10 b) strong binding of the heteroatoms to metal-
based catalyst(s) potentially reducing catalytic efficiency,11 c) lability of the nitrogen-oxygen bond 
which is prone to ring opening even under relatively mild reducing conditions,12 as well as d) 
achieving satisfactory enantiocontrol. Accordingly, the asymmetric reduction of isoxazoles under 
mild conditions with appreciable enantioselectivity is of considerable challenge in organic synthesis. 
To the best of our knowledge, the sole example of said work has very recently been reported by the 
group of Kawano.13  
Our group having improved on the antecedent Noyori’s catalyst,14 fashioned an additional tether 
which links the arene ring with the sulfonyl-protected 1,2-diphenylethylene-1,2-diamine ligand. This 
3-point attachment to the ruthenium metal centre enhances the stability of the organometallic (1), 
engendering enhancements in reaction rates.15 Simultaneous operation of two interactions may 
influence enantiocontrol: (a) an attractive CH/π (electronic) interaction between the arene ring of the 
catalyst and the π cloud of the substrate, and (b) a repulsive SO2 lone pair/ π repulsion between the 
oxygen atoms of the SO2 moiety of the catalyst and the π cloud of the substrate, typically a ketone 
containing an electron rich aromatic group (Scheme 1). These synergistic effects cumulate to give a 
highly robust and effective catalytic system, allowing for advancements on the asymmetric reduction 
of a handful of substrate classes,16 including the challenging enantioselective reduction of α,α’-
heteroatomic ketones under mild conditions.17 Seeking to broaden the scope of these tethered catalysts, 
we envisioned the enantioselective reduction of prochiral isoxazoles or their derivatives thereof. 
Herein, we divulge the asymmetric reduction of 5-arylisoxazolium salts, affording a series of optically 
active Δ4-isoxazolines in moderate to good yields and enantioselectivities. 
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Scheme 1. Mechanistic insights of asymmetric reduction employing 1 as the catalyst for ATH of 
aromatic ketones. 
We began the study by attempting the direct reduction of 3-methyl-5-phenylisozaxole in the 
presence of 1a (Figure 1) as well as a Pd(II) co-catalyst, in the hope that the latter would aid in 
activation of the C=N bond for reduction. Asymmetric transfer hydrogenation (ATH) conditions were 
selected for they are considerably milder than pressure hydrogenation which customarily require 
heating, hence reducing the prospect of thermal induced heterocyclic ring opening18 upon C=N 
reduction if any. However, the desired activation by the co-catalyst, in conjunction with a high 
possibility of protonation at the heterocyclic nitrogen (reaction was conducted in a weakly acidic 
medium) was inadequate, resulting in a lack of product formation. Determined to overcome the 
obstacle, a methyl group was introduced onto the nitrogen in hopes of achieving our objectives.       
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Figure 1. Variation of functional groups in 1. 
 
Employing 2,3-dimethyl-5-phenylisoxazolium tetrafluoroborate (2a) as the prototypical substrate, 
the ATH reaction was re-examined. The desired reaction worked favourably in acetone, affording the 
product in moderate yield and enantioselectivity. Equally important is that the C=N bond is 
exclusively reduced and that no heterocyclic ring opening product ensued. Encouraged by these 
outcomes, reaction conditions were optimized and the results presented in Table 1. 
Owing to solubility considerations, the reaction was initially conducted in acetone which the salt 
was fairly soluble in (Table 1, entry 1). However, employment of a mixed system of chloroform and 
acetone (10% v/v) afforded improved yields, albeit poor solubility of the reactant at the onset of the 
reaction (Table 1, entry 2). A handful of catalysts (1) as shown in Figure 1 were studied (Table 1, 
entries 2-6), with (R,R)-1b and 1c producing the best enantiomeric excess at 73%. The latter however 
gave a slight superior yield at 51% and as such was selected as the catalyst of choice for further 
investigation. An increase in catalyst loading from 3 to 5 mol% led to a modest improvement in ee 
(Table 1, entry 7), while substituting chloroform with dichloromethane (DCM) or ethyl acetate in the 
mixed system culminated in significant advancement in yields (Table 1, entry 8 and 9). As we 
Table 1. Optimization of conditions for the (R,R)-1 catalyzed asymmetric transfer reduction of 2,3-
dimethyl-5-phenylisoxazolium tetrafluoroborate 2a.a 
N+
O
BF4
-
+
HCO2H/Et3N
(5:2)
Cat. (R,R)-1
solvent(s)
N2, >16hrs N
O
*
2a 3a  
Entry Cat. / Loading Solvent Yieldb eec 
1 1a / 3% acetone 63 69 
2 1a / 3% CHCl3/acetone (10%) 72 72 
3 1b / 3% CHCl3/acetone (10%) 42 73 
4 1c / 3% CHCl3/acetone (10%) 51 73 
5 1d / 3% CHCl3/acetone (10%) 42 32 
6 1e / 3% CHCl3/acetone (10%) 88 64 
7 1c / 5% CHCl3/acetone (10%) 50 75 
8 1c / 5% DCM/acetone (10%) 85 77 
9 1c / 5% EtOAc/acetone (10%) 75 70 
10 1c / 5% THF 87 70 
11 1c / 5% DCM 91 78 
12 1c / 5% CHCl3 85 78 
13 1c / 5% neat 0 - 
14d 1c / 5% DCM 90 78 
 
a Reaction conditions: ca. 0.15 mmol 2a, [2a] = 0.25M [v/v (HCO2H/Et3N : solvent) = 1:7], reaction time = >16 
hrs, temperature = 15 ⁰ C to rt ; b Isolated yield; c Enantiomeric excess as determined by chiral HPLC; d 
Temperature = 0 ⁰ C to rt. 
 
postulated that the presence of acetone could negatively impact effective extraction of product during 
work-up19 hence reducing isolated yields, the investigation subsequently switched to the employment 
of pure solvent systems (Table 1, entries 10-13) with DCM affording the best outcomes at 91% yield 
and 78% ee. Omission of solvents, neat in triethylamine and formic acid solution gave no products 
(Table 1, entry 13). A lowering in temperature upon commencement of the reaction from 15 to 0 ⁰ C 
aimed to improve enantioselectivity. Surprisingly, it produced identical results within tolerable 
experimental limits as with the higher temperature (Table 1, entries 11 & 14); the lower temperature 
was selected due to the ease of starting at 0 ⁰ C. With the optimal conditions established, a series of 
representative arylisoxazolium salts 2 were screened and the outcomes displayed in Table 2. The 
majority of the substrates bearing various substituents on the phenyl ring afforded a relatively 
consistent degree of enantioenrichment (Table 2, entries 1-9), with the electron-withdrawing analog 2i 
producing a modest reduction in ee at 72% (Table 2, entry 9). Unlike the well-understood transition 
state (TS) control that operates for ketone reduction, where 1) CH/π interaction favours the TS leading 
to the major enantiomer (Scheme 1), and 2) repulsive interaction destabilises the TS leading to the 
minor enantiomer;20 enantiocontrol during C=N bond reduction is less well understood. Nevertheless, 
our group21 and others22 have proposed that the major TS leading to imine reduction adopt an “open” 
TS (whilst retaining the stabilising CH/π interaction) as opposed to the cyclic (closed) TS involved in 
ketone reduction. Translating this proposition to the current system means that the observed 
stereocontrol could be attributed to the lesser or weaker extent of CH/π interaction within the 
transition state between the catalyst (1c) and 2i, for the electronically deficient arene ring in 1c 
 
Table 2. Substrate scope for the (R,R)-1c catalyzed asymmetric transfer hydrogenation of 
arylisoxazolium salts 2.a 
N+
O
R
Ar
BF4
-
+
HCO2H/Et3N
(5:2)
(R,R)-1c [5 mol%]
DCM
0 °C to rt
N2, >16hrs
N
OAr
*
R
2 3  
Entry Product Ar R Yieldb eec 
1 3a Ph Me 90 78 
2 3b 1-Nap Me 93 76 
3 3c 2-Nap Me 88 79 
4 3d 4-MeC6H4 Me 83 80 
5 3e 4-MeOC6H4 Me 87 77 
6 3f 3-MeOC6H4 Me 78 80 
7 3g 
 
Me  80 78  
8 3h 2-MeOC6H4 Me 85 75 
9 3i 4-ClC6H4 Me 89 72 
10 3j 2-furyl Me 68 62 
11 3k 2-thiophene Me 67 73 
12 3l 3-thiophene Me 70 81 
13 3m Ph Ph 73 43 
a Reaction conditions: ca. 0.15 mmol 2, [2] = 0.25M [v/v (HCO2H/Et3N : DCM) = 1:7], reaction time = >16 hrs, 
temperature =  0 ⁰ C to rt; b Isolated yield; c Enantiomeric excess as determined by chiral HPLC. 
O
O
 favours an electron-rich ring over a poorer analog in 2 (Figure 2). 
 
Figure 2. Postulated stereochemical perspective of the electronic interaction between (R,R)-1c and 
isoxazolium salts 2. 
 
Substrates possessing a heterocyclic ring generally produced poorer yields but comparable 
enantioselectivities compared to phenyl substituted derivatives (Table 2, entries 10-12). Isoxazolium 
2m bearing a 3-phenyl group in place of the typical methyl is a noteworthy example for it expectedly 
afforded a pronounced reduction in enantioenrichment (Table 2, entry 13). By virtue of the 2 phenyl 
rings present in 2m, the newly added 3-phenyl ring now competes with the 5-positioned moiety for 
electronic interaction with the catalyst, bringing about a greater probability of nucleophilic hydride 
attack on both faces of the prochiral iminium carbon centre (Figure 3). A lowered degree of optical 
enrichment ensued, but more importantly, it supports and validates the mechanistic model whereby 
the aforementioned edge-face electronic interaction between the substrate and the catalyst is pivotal in 
imparting enantiocontrol. 
 
Figure 3. Competitive binding by 3-substituted phenyl to (R,R)-1c, bringing about poor optical 
enrichment of the corresponding product. 
 
In conclusion, the employment of a tethered Noyori-type catalyst for the mild asymmetric 
reduction of arylisoxazolium tetrafluoroborate salts is reported. No undesired heterocyclic ring 
opening was observed subsequent to iminium reduction. The employment of a 3,5-diphenyl substrate 
which expectedly produced a poorer outcome validates the established mechanism for the reduction of 
various substrates, reinforcing our understanding of the aforementioned class of ruthenium catalysts. 
 
Experimental Section 
General Experimental. Analytical grade solvents were used directly without further purification as 
purchased from commercial sources: dichloromethane (DCM), acetone and tetrahydrofuran from 
Merck; chloroform, ethyl acetate and petroleum spirit from Fischer Scientific. Chiral tethered 
ruthenium catalysts (R,R)-1 supplied by Johnson Matthey, benzoylacetone and dibenzoylmethane 
from Sigma-Aldrich and trimethyl oxonium tetrafluoroborate (95%) from Acros Organics were used 
directly without further purification. Flash chromatography on silica was conducted on Sigma Aldrich 
silica gel (technical grade, pore size 60Å, 230-400 mesh, 40-63 µm particle size). Room temperature 
is defined to be approximately 21 oC. 
NMR spectra were recorded on Bruker Avance 300 or Bruker Avance III HDF 500 spectrometers. 
1H NMR spectra chemical shifts were reported in δ ppm relative to chloroform-d (δ = 7.26 ppm) or 
acetone-d6 (δ = 2.05 ppm). Multiplicities were given as: s (singlet), d (doublet), t (triplet), q (quartet) 
and m (multiplet). The number of protons (n) for a given resonance was indicated by nH while 
coupling constants were reported as J value in Hertz (Hz). 13C NMR spectra chemical shifts were 
recorded relative to solvent resonance (CDCl3: δ = 77.26 ppm or (CD3)2CO δ = 29.84 or 206.26 ppm). 
Optical rotations of optically active amines were measured in the specified solution using a 2 dm cell 
with an Optical Activity Ltd. AA-1000 polarimeter. Chiral HPLC was performed on a Hewlett 
Packard 1050 HPLC machine incorporating a Diacel CHIRAPAK® IC, AD-H or CHIRALCEL® OJ, 
OD-H column. 
General Procedure A for the Syntheses of Isoxazolium Salts with Dimethylsulphate. 
Procedure was adapted and modified from J. Heterocyclic Chem. 2003, 40, 1097. A mixture of the 
isoxazole (1 eq.) and dimethylsulphate (1.1 eq.) was refluxed in anhydrous toluene for 48-72 hours. 
Toluene was removed via rotary evaporation and a solution of sodium tetrafluoroborate (4 eq.) was 
added to the reaction flask before cooling in an ice-bath. Crystals/solids formed were obtained by 
filtration and subsequently dried under high vacuum to afford isoxazolium salts (2). 
General Procedure B for the Syntheses of Isoxazolium Salts with Trimethyloxonium   
Tetrafluoroborate. Procedure was adapted and modified from Angew. Chem. Int. Ed. 2008, 47, 7446. 
To a nitrogen filled 2-neck RBF was charged with the isoxazole (1 eq.) and anhydrous DCM before 
cooling with an ice bath. Trimethyloxonium tetraflurorborate (0.98 eq.) was subsequently added and 
the mixture allowed to stir overnight from 0 oC to room temperature (ice bath allowed to melt). 
Several drops of methanol were added to quench the reaction before subjecting the reaction flask to 
rotary evaporation. The residue was triturated with diethyl ether, filtered and washed twice with 
diethyl ether to afford 2. 
General Procedure C for the (R,R)-1 catalyzed asymmetric transfer hydrogenation (ATH) of 
2. To a nitrogen flushed Schlenk tube was charged with isoxazolium tetrafluoroborate salt 2 (ca. 0.15 
mmol) and catalyst (R,R)-1 (3-5 mol%). Analytical grade solvent(s) were added to the mixture and 
cooled (0 or 15 oC) with stirring before addition of a 5:2 formic acid/triethylamine (TEAF) solution 
(v/v solvent(s) : TEAF = 7:1, [2] = 0.25M). The mixture was stirred overnight (> 16 hrs, 0/15 oC to rt) 
before quenching the unreacted formic acid with excess saturated sodium hydrogen carbonate (ca. 2 
mL). The biphasic mixture was extracted 4 times with ethyl acetate and twice with DCM. Combined 
organic layers were concentrated then purified by flash chromatography on silica gel (eluent: 
petroleum spirit/ethyl acetate) to afford optically enriched Δ4-isoxazolines (3). 
2,3-dimethyl-5-phenylisoxazolium tetrafluoroborate 2a. Prepared in accordance to General 
Procedure A as colourless crystals (1.33g, 66%). 1H ((CD3)2CO, 500 MHz): 2.84 (s, 3H), 4.51 (s, 3H), 
7.67-7.70 (m, 3H), 7.74-7.77 (m, 1H), 8.05 (d, 2H, J = 8Hz); 13C (jmod) ((CD3)2CO, 126 MHz): 12.4 
(1C), 39.0 (1C), 106.2 (1C), 124.2 (1C), 128.0 (2C), 130.7 (2C), 134.6 (1C), 162.3 (1C), 170.9 (1C); 
Melting range = 148-150 oC; HRMS (ESI-TOF) calcd. for C11H12NO [M-BF4-]+: 174.0913, found 
174.0916. 
2,3-dimethyl-5-(1-napthyl)isoxazolium tetrafluoroborate 2b. Prepared in accordance to General 
Procedure B as off-white solids (1.03g, 80%). 1H ((CD3)2CO, 500 MHz): 2.94 (s, 3H), 4.61 (s, 3H), 
7.71- 7.77 (m, 4H), 8.12-8.15 (m, 2H), 8.32 (d, 2H, J = 8Hz), 8.38 (d, 2H, J = 9Hz); 13C (jmod) 
((CD3)2CO, 126 MHz): 12.5 (1C), 39.2 (1C), 110.1 (1C), 121.4 (1C), 121.4 (1C), 124.9 (1C), 126.3 
(1C), 128.2 (1C), 129.7 (1C), 130.1 (1C), 130.6 (1C), 131.1 (1C), 135.0 (1C), 161.9 (1C), 171.2 (1C); 
Melting range = 139-141 oC; HRMS (ESI-TOF) calcd. for C15H14NO [M-BF4-]+: 224.1070, found 
224.1074. 
2,3-dimethyl-5-(2-napthyl)isoxazolium tetrafluoroborate 2c. Prepared in accordance to General 
Procedure B as off-white solids (0.27g, 63%). 1H ((CD3)2CO, 500 MHz): 2.89 (s, 3H), 4.56 (s, 3H), 
7.69- 7.78 (m, 3H), 8.02-8.19 (m, 4H), 8.72 (s, 1H); 13C (jmod) ((CD3)2CO, 126 MHz): 12.4 (1C), 
39.1 (1C), 106.4 (1C), 121.4 (1C), 123.2 (1C), 128.8 (1C), 129.0 (1C), 129.5 (1C), 130.2 (1C), 130.3 
(1C), 130.7 (1C), 133.7 (1C), 136.3 (1C), 162.3 (1C), 171.1 (1C); Melting range = 169-170 oC; 
HRMS (ESI-TOF) calcd. for C15H14NO [M-BF4-]+: 224.1070, found 224.1068. 
2,3-dimethyl-5-(4-methylphenyl)isoxazolium tetrafluoroborate 2d. Prepared in accordance to 
General Procedure A as white solids (0.23g, 24%). 1H ((CD3)2CO, 500 MHz): 2.50 (s, 3H), 2.84 (s, 
3H), 4.50 (s, 3H), 7.50 (d, 2H, J = 8Hz), 7.61 (s, 1H), 7.94 (d, 2H, J = 8Hz); 13C (jmod) ((CD3)2CO, 
126 MHz): 12.3 (1C), 21.7 (1C), 38.9 (1C), 105.5 (1C), 121.5 (1C), 128.0 (2C), 131.3 (2C), 145.9 
(1C), 162.1 (1C), 171.2 (1C); Melting range = 136-139 oC; HRMS (ESI-TOF) calcd. for C12H14NO 
[M-BF4-]+: 188.1070, found 188.1067. 
2,3-dimethyl-5-(4-methoxyphenyl)isoxazolium tetrafluoroborate 2e. Prepared in accordance to 
General Procedure B as white solids (0.26g, 65%). 1H ((CD3)2CO, 500 MHz): 2.82 (s, 3H), 3.95 (s, 
3H), 4.48 (s, 3H), 7.21 (d, 2H, J = 9Hz), 7.51 (s, 1H), 8.01 (d, 2H, J = 9Hz); 13C (jmod) ((CD3)2CO, 
126 MHz): 12.3 (1C), 38.8 (1C), 56.3 (1C), 104.4 (1C), 116.2 (2C), 116.4 (1C), 130.2 (2C), 161.9 
(1C), 165.1 (1C), 171.2 (1C); Melting range = 166-167 oC; HRMS (ESI-TOF) calcd. for C12H14NO2 
[M-BF4-]+: 204.1019, found 204.1018. 
2,3-dimethyl-5-(3-methoxyphenyl)isoxazolium tetrafluoroborate 2f. Prepared in accordance to 
General Procedure B as white solids, (0.34g, 73%). 1H ((CD3)2CO, 500 MHz): 2.86 (s, 3H), 3.92 (s, 
3H), 4.52 (s, 3H), 7.30-7.32 (m, 1H), 7.58-7.63 (m, 3H), 7.70 (s, 1H); 13C (jmod) ((CD3)2CO, 126 
MHz): 12.4 (1C), 39.0 (1C), 56.2 (1C), 106.4 (1C), 112.9 (1C), 120.2 (1C), 120.6 (1C), 125.3 (1C), 
132.0 (1C), 161.4 (1C), 162.3 (1C), 170.8 (1C); Melting range = 170-171 oC; HRMS (ESI-TOF) calcd. 
for C12H14NO2 [M-BF4-]+: 204.1019, found 204.1021. 
2,3-dimethyl-5-(3,4-methylenedioxyphenyl)isoxazolium tetrafluoroborate 2g. Prepared in 
accordance to General Procedure B as off-white solids (0.50g, 66%). 1H ((CD3)2CO, 500 MHz): 2.83 
(s, 3H), 4.48 (s, 3H), 6.22 (s, 2H), 7.14 (d, 1H, J = 8Hz), 7.50-7.52 (m, 2H), 7.65 (dd, 1H, J = 3,8Hz); 
13C (jmod) ((CD3)2CO, 126 MHz): 12.3 (1C), 38.8 (1C), 103.8 (1C), 104.8 (1C), 107.3 (1C), 110.3 
(1C), 117.8 (1C), 124.3 (1C), 150.0 (1C), 153.6 (1C), 162.0 (1C), 170.9 (1C); Melting range = 162-
164 oC; HRMS (ESI-TOF) calcd. for C12H12NO3 [M-BF4-]+: 218.0812, found 218.0819. 
2,3-dimethyl-5-(2-methoxyphenyl)isoxazolium tetrafluoroborate 2h. Prepared in accordance to 
General Procedure B as white solids (0.30g, 74%). 1H ((CD3)2CO, 500 MHz): 2.85 (s, 3H), 4.10 (s, 
3H), 4.50 (s, 3H), 7.22 (t, 1H, J = 8Hz), 7.37 (d, 1H, J = 9Hz), 7.62 (s, 1H), 7.71-7.75 (m, 1H), 7.96 
(dd, 1H, J = 1,8Hz); 13C (jmod) ((CD3)2CO, 126 MHz): 12.3 (1C), 38.8 (1C), 56.7 (1C), 106.1 (1C), 
112.7 (1C), 113.6 (1C), 122.2 (1C), 129.0 (1C), 136.4 (1C), 159.5 (1C), 161.8 (1C), 167.8 (1C); 
Melting range = 218-219 oC; HRMS (ESI-TOF) calcd. for C12H14NO2 [M-BF4-]+: 204.1019, found 
204.1019. 
2,3-dimethyl-5-(4-chlorophenyl)isoxazolium tetrafluoroborate 2i. Prepared in accordance to 
General Procedure A as white solids (0.82g, 66%). 1H ((CD3)2CO, 500 MHz): 2.88 (s, 3H), 4.54 (s, 
3H), 7.72 (s, 1H), 7.74 (d, 2H, J = 9Hz), 8.09 (d, 2H, J = 9Hz); 13C (jmod) ((CD3)2CO, 126 MHz): 
12.5 (1C), 39.1 (1C), 106.7 (1C), 123.0 (1C), 129.8 (2C), 131.0 (2C), 140.4 (1C), 162.4 (1C), 169.9 
(1C); Melting range = 163-164 oC; HRMS (ESI-TOF) calcd. for C12H11NOCl [M-BF4-]+: 208.0524 
and 210.0494, found 208.0523 and 210.0491. 
2,3-dimethyl-5-(2-furyl)isoxazolium tetrafluoroborate 2j. Prepared in accordance General 
Procedure A as pale brown crystals (0.75g, 35%). 1H ((CD3)2CO, 500 MHz): 2.83 (s, 3H), 4.46 (s, 
3H), 6.88-6.89 (m, 1H), 7.42 (s, 1H), 7.60 (d, 1H, J = 4Hz), 8.09 (s, 1H); 13C (jmod) ((CD3)2CO, 126 
MHz): 12.4 (1C), 39.0 (1C), 104.6 (1C), 114.5 (1C), 118.8 (1C), 140.0 (1C), 149.9 (1C), 161.5 (1C), 
162.1 (1C); Melting range = 144-146 oC; HRMS (ESI-TOF) calcd. for C9H10NO2 [M-BF4-]+: 
164.0706, found 164.0709. 
2,3-dimethyl-5-(2-thiophene)isoxazolium tetrafluoroborate 2k. Prepared in accordance to 
General Procedure B as off-white solids (0.49g, 82%). 1H ((CD3)2CO, 500 MHz): 2.83 (s, 3H), 4.48 (s, 
3H), 7.41 (t, 1H, J = 4Hz), 7.51 (s, 1H), 8.07 (d, 1H, J = 4Hz), 8.13 (d, 1H, J = 5Hz); 13C (jmod) 
((CD3)2CO, 126 MHz): 12.3 (1C), 38.9 (1C), 105.0 (1C), 125.1 (1C), 130.5 (1C), 134.0 (1C), 135.5 
(1C), 162.2 (1C), 166.3 (1C); Melting range = 171-174 oC; HRMS (ESI-TOF) calcd. for C9H10NOS 
[M-BF4-]+: 180.0478, found 180.0480. 
2,3-dimethyl-5-(3-thiophene)isoxazolium tetrafluoroborate 2l. Prepared in accordance to 
General Procedure B as pale brown solids (0.35g, 80%). 1H ((CD3)2CO, 500 MHz): 2.83 (s, 3H), 4.47 
(s, 3H), 7.51 (s, 1H), 7.72 (d, 1H, J = 3Hz), 7.85-7.86 (m, 1H), 8.55-8.55 (m, 1H); 13C (jmod) 
((CD3)2CO, 126 MHz): 12.3 (1C), 38.8 (1C), 105.6 (1C), 125.5 (1C), 126.3 (1C), 130.4 (1C), 132.1 
(1C), 162.1 (1C), 167.0 (1C); Melting range = 84-87 oC; HRMS (ESI-TOF) calcd. for C9H10NOS [M-
BF4-]+: 180.0478, found 180.0479. 
2-dimethyl-3,5-diphenylsoxazolium tetrafluoroborate 2m. Prepared in accordance to General 
Procedure B as white solids (0.22g, 37%). 1H ((CD3)2CO, 500 MHz): 4.70 (s, 3H), 7.72-7.86 (m, 6H), 
8.06 (d, 2H, J = 8Hz), 8.12 (s, 1H), 8.17 (d, 2H, J = 7Hz); 13C (jmod) ((CD3)2CO, 126 MHz): 41.0 
(1C), 105.6 (1C), 123.8 (1C), 124.3 (1C), 128.3 (2C), 103.5 (2C), 130.8 (2C), 130.8 (2C), 134.6 (1C), 
135.0 (1C), 161.5 (1C), 171.7 (1C); Melting range = 224-225 oC; HRMS (ESI-TOF) calcd. for 
C16H14NO [M-BF4-]+: 236.1070, found 236.1073. 
(+)-2,3-dimethyl-5-phenyl-2,3-dihydroisoxazole 3a. Prepared in accordance to General 
Procedure C as a yellow oil, (Eluent: pet. ether / ethyl acetate (v/v) = 5/1, 22.0 mg, 90% yield, 78% 
ee). 1H (CDCl3, 500 MHz): 1.28 (d, 3H, J = 7Hz), 2.83 (s, 3H), 3.86 (br. s, 1H), 5.23 (d, 1H, J = 3Hz), 
7.31-7.36 (m, 3H), 7.54 (d, 2H, J = 7Hz); 13C (jmod) ((CD3)2CO, 126 MHz): 22.1 (1C), 46.9 (1C), 
69.0 (1C), 97.2 (1C), 125.8 (2C), 128.6 (2C), 129.0 (1C), 129.4 (1C), 152.0 (1C); HRMS (ESI-TOF) 
calcd. for C11H13NONa [M+Na]+: 198.0889, found 198.0884; HPLC (Diacel OD-H column, 
Hexane:IPA = 96:4, detection wavelength: λ = 254 nm, flow rate = 1 mL/min): t1 = 5.94 min, t2 = 7.22 
min; [α]D25 = +58.80o (c = 0.99, CHCl3). 
(+)-2,3-dimethyl-5-(1-napthyl)-2,3-dihydroisoxazole 3b. Prepared in accordance to General 
Procedure C as a colourless oil (Eluent: pet. ether / ethyl acetate (v/v) = 5/1, 30.5 mg, 93% yield, 76% 
ee). 1H (CDCl3, 500 MHz): 1.40 (d, 3H, J = 7Hz), 2.95 (s, 3H), 3.98 (br. s, 1H), 5.20 (d, 1H, J = 3Hz), 
7.44-7.55 (m, 4H), 7.67 (d, 1H, J = 7Hz), 7.85 (d, 2H, J = 8Hz), 8.38 (d, 1H, J = 9Hz); 13C (jmod) 
((CD3)2CO, 126 MHz): 22.4 (1C), 46.9 (1C), 69.2 (1C), 101.8 (1C), 125.3 (1C), 125.7 (1C), 126.2 
(1C), 126.7 (1C), 127.1 (1C), 127.2 (1C), 128.6 (1C), 129.8 (1C), 131.3 (1C), 133.9 (1C), 151.7 (1C); 
HRMS (ESI-TOF) calcd. for C15H16NO [M+H]+: 226.1226, found 226.1228; HPLC (Diacel OD-H 
column, Hexane:IPA = 98:2, detection wavelength: λ = 254 nm, flow rate = 1 mL/min): t1 = 15.98 
min, t2 = 21.04 min; [α]D26 = +19.55o (c = 0.99, CHCl3). 
(+)-2,3-dimethyl-5-(2-napthyl)-2,3-dihydroisoxazole 3c Prepared in accordance to General 
Procedure C as a pale yellow oil (Eluent: pet. ether / ethyl acetate (v/v) = 5/1, 29.1 mg, 88% yield, 79% 
ee): 1H (CDCl3, 500 MHz): 1.32 (d, 3H, J = 7Hz), 2.88 (s, 3H), 3.92 (br. s, 1H), 5.37 (d, 1H, J = 3Hz), 
7.47-7.49 (m, 2H), 7.60-7.62 (m, 1H), 7.79-7.86 (m, 3H), 8.01 (s, 1H); 13C (jmod) ((CD3)2CO, 126 
MHz): 22.1 (1C), 46.9 (1C), 69.1 (1C), 98.1 (1C), 123.7 (1C), 124.8 (1C), 126.6 (1C), 126.7 (1C), 
126.7 (1C), 127.9 (1C), 128.2 (1C), 128.6 (1C), 133.3 (1C), 133.6 (1C), 152.0 (1C); HRMS (ESI-TOF) 
calcd. for C15H16NO [M+H]+: 226.1226, found 226.1224; HPLC (Diacel OD-H column, Hexane:IPA 
= 98:2, detection wavelength: λ = 254 nm, flow rate = 1 mL/min): t1 = 14.72 min, t2 = 18.56 min; 
[α]D25 = +58.77o (c = 1.02, CHCl3). 
(+)-2,3-dimethyl-5-(4-methylphenyl)-2,3-dihydroisoxazole 3d. Prepared in accordance to 
General Procedure C as a colourless oil (Eluent: pet. ether / ethyl acetate (v/v) = 5/1, 23.7 mg, 83% 
yield, 80% ee). 1H (CDCl3, 300 MHz): 1.27 (d, 3H, J = 6Hz), 2.35 (s, 3H), 2.82 (s, 3H), 3.85 (br. s, 
1H), 5.17 (d, 1H, J = 2Hz), 7.15 (d, 2H, J = 8Hz), 7.43 (d, 2H, J = 8Hz); 13C (jmod) ((CD3)2CO, 126 
MHz): 21.6 (1C), 22.2 (1C), 46.8 (1C), 68.9 (1C), 96.3 (1C), 125.7 (2C), 126.6 (1C), 129.2 (2C), 
139.0 (1C), 152.0 (1C); HRMS (ESI-TOF) calcd. for C12H15NONa [M+Na]+: 212.1046, found 
212.1049; HPLC (Diacel IC column, Hexane:IPA = 97:3, detection wavelength: λ = 254 nm, flow rate 
= 1 mL/min): t1 = 8.34 min, t2 = 9.34 min; [α]D25 = +53.77o (c = 1.01, CHCl3). 
(+)-2,3-dimethyl-5-(4-methoxyphenyl)-2,3-dihydroisoxazole 3e. Prepared in accordance to 
General Procedure C as a colourless oil (Eluent: pet. ether / ethyl acetate (v/v) = 5/1, 26.0 mg, 87% 
yield, 77% ee). 1H (CDCl3, 500 MHz): 1.26 (d, 3H, J = 6Hz), 2.81 (s, 3H), 3.82 (s, 3H), 3.84 (br. s, 
1H), 5.09 (d, 1H, J = 2Hz), 6.87 (d, 2H, J = 9Hz), 7.47 (d, 2H, J = 9Hz); 13C (jmod) ((CD3)2CO, 126 
MHz): 22.2 (1C), 46.8 (1C), 55.6 (1C), 69.0 (1C), 95.3 (1C), 114.0 (2C), 122.1 (1C), 127.2 (2C), 
151.8 (1C), 160.2 (1C); HRMS (ESI-TOF) calcd. for C12H16NO2 [M+H]+: 206.1176, found 206.1178; 
HPLC (Diacel AD-H column, Hexane:IPA = 97:3, detection wavelength: λ = 254 nm, flow rate = 1 
mL/min): t1 = 9.05 min, t2 = 10.41 min; [α]D22 = +19.95o (c = 1.01, CHCl3). 
(+)-2,3-dimethyl-5-(3-methoxyphenyl)-2,3-dihydroisoxazole 3f. Prepared in accordance to 
General Procedure C as a colourless oil (Eluent: pet. ether / ethyl acetate (v/v) = 10/1, 23.2 mg, 78% 
yield, 80% ee). 1H (CDCl3, 300 MHz): 1.31 (d, 3H, J = 6Hz), 2.86 (s, 3H), 3.85 (s, 3H), 3.89 (br. s, 
1H), 5.27 (d, 1H, J = 2Hz), 6.88-6.91 (m, 1H), 7.10 (s, 1H), 7.16-7.18 (m, 1H), 7.29-7.31 (m, 1H); 13C 
(jmod) ((CD3)2CO, 126 MHz): 22.1 (1C), 46.9 (1C), 55.5 (1C), 69.0 (1C), 97.6 (1C), 110.9 (1C), 
115.0 (1C), 118.4 (1C), 129.6 (1C), 130.7 (1C), 151.9 (1C), 159.8 (1C); HRMS (ESI-TOF) calcd. for 
C12H16NO2 [M+H]+: 206.1176, found 206.1176; HPLC (Diacel IC column, Hexane:IPA = 97:3, 
detection wavelength: λ = 254 nm, flow rate = 1 mL/min): t1 = 11.98 min, t2 = 14.25 min; [α]D23 = 
+39.93o (c = 0.99, CHCl3). 
(+)-2,3-dimethyl-5-(3,4-methylenedioxyphenyl)-2,3-dihydroisoxazole 3g. Prepared in 
accordance to General Procedure C as a colourless oil (Eluent: pet. ether / ethyl acetate (v/v) = 10/1, 
26.5 mg, 80% yield, 78% ee). 1H (CDCl3, 500 MHz): 1.26 (d, 3H, J = 6Hz), 2.81 (s, 3H), 3.83 (br. s, 
1H), 5.08 (d, 1H, J = 3Hz), 5.97 (s, 2H), 6.78 (d, 1H, J = 8Hz), 7.00 (d, 1H, J = 1Hz), 7.06 (dd, 1H, J 
= 2,8Hz); 13C (jmod) ((CD3)2CO, 126 MHz): 22.2 (1C), 46.8 (1C), 69.0 (1C), 96.0 (1C), 101.4 (1C), 
106.4 (1C), 108.4 (1C), 119.9 (1C), 123.5 (1C), 147.8 (1C), 148.3 (1C), 151.7 (1C); HRMS (ESI-TOF) 
calcd. for C12H14NO3 [M+H]+: 220.0968, found 220.0964; HPLC (Diacel OD-H column, Hexane:IPA 
= 98:2, detection wavelength: λ = 254 nm, flow rate = 1 mL/min): t1 = 17.47 min, t2 = 21.52 min; 
[α]D21 = +59.24o (c = 1.01, CHCl3). 
(+)-2,3-dimethyl-5-(2-methoxyphenyl)-2,3-dihydroisoxazole 3h. Prepared in accordance to 
General Procedure C as a colourless oil (Eluent: pet. ether / ethyl acetate (v/v) = 5/1, 26.1 mg, 85% 
yield, 75% ee). 1H (CDCl3, 300 MHz): 1.27 (d, 3H, J = 6Hz), 2.79 (s, 3H), 3.89 (br. s, 1H), 3.92 (s, 
3H), 5.65 (d, 1H, J = 2Hz), 6.91-6.99 (m, 2H), 7.26-7.31 (m, 1H), 7.58-7.61 (m, 1H); 13C (jmod) 
((CD3)2CO, 126 MHz): 22.1 (1C), 46.7 (1C), 55.6 (1C), 69.4 (1C), 102.3 (1C), 110.7 (1C), 118.1 (1C), 
120.6 (1C), 127.7 (1C), 129.6 (1C), 147.2 (1C), 157.1 (1C); HRMS (ESI-TOF) calcd. for C12H16NO2 
[M+H]+: 206.1176, found 206.1171; HPLC (Diacel AD-H column, Hexane:IPA = 97:3, detection 
wavelength: λ = 254 nm, flow rate = 1 mL/min): t1 = 9.33 min, t2 = 10.64 min; [α]D23 = +59.75o (c = 
1.00, CHCl3). 
(+)-2,3-dimethyl-5-(4-chlorophenyl)-2,3-dihydroisoxazole 3i. Prepared in accordance to General 
Procedure C as a colourless oil (Eluent: pet. ether / ethyl acetate (v/v) = 10/1, 28.0 mg, 89% yield, 72% 
ee). 1H (CDCl3, 500 MHz): 1.27 (d, 3H, J = 4Hz), 2.81 (s, 3H), 3.86 (br. s, 1H), 5.22 (d, 1H, J = 3Hz), 
7.31 (d, 2H, J = 9Hz), 7.45 (d, 2H, J = 9Hz); 13C (jmod) ((CD3)2CO, 126 MHz): 22.0 (1C), 46.8 (1C), 
69.0 (1C), 97.8 (1C), 127.1 (2C), 127.8 (1C), 128.8 (2C), 134.7 (1C), 151.1 (1C); HRMS (ESI-TOF) 
calcd. for C11H13NOCl [M+H]+: 210.0680 & 212.0651, found 210.0678 & 212.0650; HPLC (Diacel 
OJ column, Hexane:IPA = 98:2, detection wavelength: λ = 254 nm, flow rate = 1 mL/min): t1 = 13.66 
min, t2 = 18.55 min; [α]D22 = +39.28o (c = 1.01, CHCl3). 
(+)-2,3-dimethyl-5-(2-furyl)-2,3-dihydroisoxazole 3j. Prepared in accordance to General 
Procedure C as a pale yellow oil (Eluent: pet. ether / ethyl acetate (v/v) = 10/1, 17.1 mg, 68% yield, 
62% ee). 1H (CDCl3, 500 MHz): 1.26 (d, 3H, J = 6Hz), 2.80 (s, 3H), 3.84 (br. s, 1H), 5.20 (d, 1H, J = 
3Hz), 6.41 (dd, 1H, J = 2,3Hz), 6.48 (d, 1H, J = 4Hz), 7.41 (s, 1H); 13C (jmod) ((CD3)2CO, 126 MHz): 
21.9 (1C), 46.8 (1C), 68.8 (1C), 97.4 (1C), 108.6 (1C), 111.4 (1C), 143.2 (1C), 144.3 (1C), 144.8 (1C); 
HRMS (ESI-TOF) calcd. for C9H12NO2 [M+H]+: 166.0863, found 166.0860; HPLC (Diacel OJ 
column, Hexane:IPA = 99:1, detection wavelength: λ = 254 nm, flow rate = 1 mL/min): t1 = 10.60 
min, t2 = 18.00 min; [α]D23 = +45.74o (c = 1.02, CHCl3). 
(+)-2,3-dimethyl-5-(2-thiophene)-2,3-dihydroisoxazole 3k. Prepared in accordance to General 
Procedure C as a yellow oil (Eluent: pet. ether / ethyl acetate (v/v) = 10/1, 18.3 mg, 67% yield, 73% 
ee). 1H (CDCl3, 500 MHz): 1.27 (d, 3H, J = 7Hz), 2.82 (s, 3H), 3.84 (br. s, 1H), 5.13 (d, 1H, J = 3Hz), 
7.00 (dd, 1H, J = 4,5Hz), 7.21 (d, 1H, J = 4Hz), 7.27 (d, 1H, J = 5Hz); 13C (jmod) ((CD3)2CO, 126 
MHz): 22.0 (1C), 46.8 (1C), 69.1 (1C), 97.3 (1C), 125.8 (1C), 126.1 (1C), 127.6 (1C), 131.6 (1C), 
147.2 (1C); HRMS (ESI-TOF) calcd. for C9H11NOSNa [M+Na]+: 204.0454, found 204.0451; HPLC 
(Diacel OD-H column, Hexane:IPA = 98:2, detection wavelength: λ = 254 nm, flow rate = 1 mL/min): 
t1 = 9.34 min, t2 = 12.24 min; [α]D20 = +67.69o (c = 1.00, CHCl3). 
(+)-2,3-dimethyl-5-(3-thiophene)-2,3-dihydroisoxazole 3l. Prepared in accordance to General 
Procedure C as a pale yellow oil (Eluent: pet. ether / ethyl acetate (v/v) = 10/1, 18.7 mg, 70% yield, 
81% ee). 1H (CDCl3, 500 MHz): 1.26 (d, 3H, J = 7Hz), 2.81 (s, 3H), 3.83 (br. s, 1H), 5.08 (d, 1H, J = 
3Hz), 7.18 (d, 1H, J = 5Hz), 7.28-7.29 (m, 1H), 7.41 (d, 1H, J = 3Hz); 13C (jmod) ((CD3)2CO, 126 
MHz): 22.1 (1C), 46.9 (1C), 68.8 (1C), 97.0 (1C), 122.6 (1C), 125.8 (1C), 126.2 (1C), 130.7 (1C), 
148.4 (1C); HRMS (ESI-TOF) calcd. for C9H11NOSNa [M+Na]+: 204.0454, found 204.0450; HPLC 
(Diacel OD-H column, Hexane:IPA = 98:2, detection wavelength: λ = 254 nm, flow rate = 1 mL/min): 
t1 = 11.42min, t2 = 15.82 min; [α]D23 = +51.90o (c = 1.01, CHCl3). 
(+)-2-dimethyl-3,5-diphenyl-2,3-dihydroisoxazole 3m. Prepared in accordance to General 
Procedure C as a pale yellow oil (Eluent: pet. ether / ethyl acetate (v/v) = 15/1, 26.4 mg, 73% yield, 
43% ee). 1H (CDCl3, 500 MHz): 2.99 (s, 3H), 4.85 (br. s, 1H), 5.38 (d, 1H, J = 5Hz), 7.28-7.61 (m, 
10H), 7.41 (d, 1H, J = 3Hz); 13C (jmod) ((CD3)2CO, 126 MHz): 47.5 (1C), 77.3 (1C), 96.0 (1C), 126.0 
(2C), 127.3 (1C), 128.0 (1C), 128.6 (2C), 128.9 (2C), 129.0 (1C), 129.3 (2C), 142.3 (1C), 152.7 (1C); 
HRMS (ESI-TOF) calcd. for C16H15NONa [M+Na]+: 260.1046, found 260.1040; HPLC (Diacel AD-
H column, Hexane:IPA = 96:4, detection wavelength: λ = 254 nm, flow rate = 1 mL/min): t1 = 
7.36min, t2 = 8.88 min; [α]D25 = +56.52o (c = 1.01, CHCl3). 
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